We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 16, 2020

Efficacy of CTC Count–Driven vs Clinician-Driven First-Line Therapy Choice in HR+, ERBB2− Metastatic Breast Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-Line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial
JAMA Oncol 2020 Nov 05;[EPub Ahead of Print], FC Bidard, W Jacot, N Kiavue, S Dureau, A Kadi, E Brain, T Bachelot, H Bourgeois, A Gonçalves, S Ladoire, H Naman, F Dalenc, J Gligorov, M Espié, G Emile, JM Ferrero, D Loirat, S Frank, L Cabel, V Diéras, L Cayrefourcq, C Simondi, F Berger, C Alix-Panabières, JY Pierga

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading